A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
Phase 2 – studying effectiveness and dosage
Conditions:
Uncontrolled Moderate to Severe Eosinophilic Asthma
Sponsor: Kymera Therapeutics Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline to Week 12 in post-bronchodilator FEV1., Change from baseline to Week 12 in ACQ-5 score, Change from baseline to Week 12 in the AQLQ(S) Global Score, Incidence of TEAEs, Incidence of treatment-emergent SAEs, Plasma PK parameter estimates of KT-621 derived from plasma concentration time data
Change from baseline to Week 12 in pre-bronchodilator FEV1.
Description
Change from baseline to Week 12 in post-bronchodilator FEV1., Change from baseline to Week 12 in ACQ-5 score, Change from baseline to Week 12 in the AQLQ(S) Global Score, Incidence of TEAEs, Incidence of treatment-emergent SAEs, Plasma PK parameter estimates of KT-621 derived from plasma concentration time data
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 121 participants
БГ